{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:22:11Z","timestamp":1781810531856,"version":"3.54.5"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP21K07466 and JP21K07855"],"award-info":[{"award-number":["JP21K07466 and JP21K07855"]}]},{"name":"JSPS KAKENHI","award":["JP19K16924"],"award-info":[{"award-number":["JP19K16924"]}]},{"name":"Japan Heart Foundation Research Grant"},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K16605"],"award-info":[{"award-number":["JP20K16605"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["JP23L12663"],"award-info":[{"award-number":["JP23L12663"]}]},{"name":"JSPS KAKENHI","award":["JP18K07533"],"award-info":[{"award-number":["JP18K07533"]}]},{"name":"Japanese Ministry of Health, Labor, and Welfare, Japan","award":["21FC0201, 21FC1002"],"award-info":[{"award-number":["21FC0201, 21FC1002"]}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP21dm0307003s0105, JP21ek0109516s0301, JP21ek0210120s0202"],"award-info":[{"award-number":["JP21dm0307003s0105, JP21ek0109516s0301, JP21ek0210120s0202"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID) is an appropriate screening tool for detecting dementia in Down\u2019s syndrome patients. However, whether this questionnaire reflects the neuropsychiatric signs of biomarker-confirmed Alzheimer\u2019s disease in DS (DS-AD) remains unknown. To address this issue, we compared the plasma phosphorylated tau (P181tau: p-tau) level of a representative AD biomarker with the total score and each sub-score of the DSQIID. The DSQIID was completed by 43 of the 56 individuals enrolled in the study. The DSQIID total scores tended to be positively associated with age, and some sub-scores increased in an age-dependent manner. DSQIID total scores and some sub-scores were also positively correlated with plasma p-tau levels, while all significant correlations disappeared after adjusting for age. Moreover, one sub-score appeared to have a significant negative correlation with plasma p-tau levels after adjusting for age. The DSQIID likely reflects age-associated behavioral changes in patients with DS. Meanwhile, their scores did not correlate with plasma p-tau after adjusting for age, suggesting that there might be room for improvement in the DSQIID for detecting DS-AD.<\/jats:p>","DOI":"10.1371\/journal.pone.0311878","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T18:30:46Z","timestamp":1733769046000},"page":"e0311878","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison between DSQIID total \/ sub-item scores and plasma p-tau elevation in adults with Down\u2019s syndrome"],"prefix":"10.1371","volume":"19","author":[{"given":"Makiko","family":"Shinomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisen","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harutsugu","family":"Tatebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-4758","authenticated-orcid":true,"given":"Fukiko","family":"Kitani-Morii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Ohmichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Menjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-2879","authenticated-orcid":true,"given":"Miho","family":"Osako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Teramukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7907-8243","authenticated-orcid":true,"given":"Toshiki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-0738","authenticated-orcid":true,"given":"Takashi","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"pone.0311878.ref001","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/ejhg.2012.294","article-title":"The population prevalence of Down\u2019s syndrome in England and Wales in 2011","volume":"21","author":"J. Wu","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"pone.0311878.ref002","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0197-4580(89)90073-0","article-title":"Cerebral amyloidosis, ageing and Alzheimer\u2019s disease; a contribution from studies on Down\u2019s syndrome.","volume":"10","author":"D. M. Mann","year":"1989","journal-title":"Neurobiol Aging"},{"key":"pone.0311878.ref003","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease","volume":"12","author":"J. Hardy","year":"1991","journal-title":"Trends Pharmacol Sci"},{"key":"pone.0311878.ref004","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrn3983","article-title":"A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.","volume":"16","author":"F. K. Wiseman","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"pone.0311878.ref005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/jir.12074","article-title":"A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome","volume":"58","author":"M. McCarron","year":"2014","journal-title":"J Intellect Disabil Res"},{"key":"pone.0311878.ref006","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/jir.12390","article-title":"A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome","volume":"61","author":"M. McCarron","year":"2017","journal-title":"J Intellect Disabil Res"},{"key":"pone.0311878.ref007","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-014-0060-7","article-title":"Pro: Are we ready to translate Alzheimer\u2019s disease modifying therapies to people with Down syndrome?","volume":"6","author":"M. S. Rafii","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"pone.0311878.ref008","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","article-title":"The pattern of amyloid accumulation in the brains of adults with Down syndrome","volume":"12","author":"T. Annus","year":"2016","journal-title":"Alzheimers Dement"},{"key":"pone.0311878.ref009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13024-020-00414-3","article-title":"Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue","volume":"15","author":"L. Lemoine","year":"2020","journal-title":"Mol Neurodegener"},{"key":"pone.0311878.ref010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","article-title":"Dementia in Down syndrome: unique insights for Alzheimer disease research.","volume":"15","author":"I. T. Lott","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"pone.0311878.ref011","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1038\/s41467-021-24319-x","article-title":"Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer\u2019s disease in adults with Down syndrome","volume":"12","author":"A. Lle\u00f3","year":"2021","journal-title":"Nat Commun"},{"key":"pone.0311878.ref012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","article-title":"Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome","volume":"12","author":"H. Tatebe","year":"2017","journal-title":"Mol Neurodegener"},{"key":"pone.0311878.ref013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11065-017-9341-9","article-title":"The Early Presentation of Dementia in People with Down Syndrome: a Systematic Review of Longitudinal Studies","volume":"27","author":"B. A. Lautarescu","year":"2017","journal-title":"Neuropsychol Rev"},{"key":"pone.0311878.ref014","doi-asserted-by":"crossref","first-page":"104148","DOI":"10.1016\/j.ridd.2021.104148","article-title":"Informant-based assessment instruments for dementia in people with intellectual disability: A systematic review and standardised evaluation.","volume":"121","author":"E. L. Zeilinger","year":"2022","journal-title":"Res Dev Disabil"},{"key":"pone.0311878.ref015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1192\/bjp.bp.106.024984","article-title":"Dementia screening questionnaire for individuals with intellectual disabilities","volume":"190","author":"S. Deb","year":"2007","journal-title":"Br J Psychiatry"},{"key":"pone.0311878.ref016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"C. H. van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"pone.0311878.ref017","first-page":"512","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2","volume":"330","author":"J. R. Sims","year":"2023","journal-title":"Randomized Clinical Trial. JAMA"},{"key":"pone.0311878.ref018","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup.","volume":"20","author":"C. R. Jack","year":"2024","journal-title":"Alzheimers Dement"},{"key":"pone.0311878.ref019","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future","volume":"284","author":"K. Blennow","year":"2018","journal-title":"J Intern Med"},{"key":"pone.0311878.ref020","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/alz.12570","article-title":"CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.","volume":"18","author":"A. Moscoso","year":"2022","journal-title":"Alzheimers Dement"},{"key":"pone.0311878.ref021","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.","volume":"19","author":"T. K. Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"pone.0311878.ref022","first-page":"98","article-title":"Specificity and sensitivity of the Japanese version of DSQIID (Dementia Screening Questionnaire for Individuals with Intellectual Disabilities).","volume":"4","author":"D. Kinoshita","year":"2010","journal-title":"The Memories of Independent Administrative Institution National Center for Person with Severe Intellectual Disabilities, Nozominosono [in Japanese]"},{"key":"pone.0311878.ref023","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","article-title":"Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study","volume":"17","author":"J. Fortea","year":"2018","journal-title":"Lancet Neurol"},{"key":"pone.0311878.ref024","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(21)00129-0","article-title":"Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study","volume":"20","author":"M. Carmona-Iragui","year":"2021","journal-title":"Lancet Neurol"},{"key":"pone.0311878.ref025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.mayocp.2013.04.024","article-title":"The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities","volume":"88","author":"J. A. Moran","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"pone.0311878.ref026","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0047-6374(88)90041-3","article-title":"The pathological association between Down syndrome and Alzheimer disease","volume":"43","author":"D. M. Mann","year":"1988","journal-title":"Mech Ageing Dev"},{"key":"pone.0311878.ref027","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0022-2275(20)38431-5","article-title":"Genetic studies of human apolipoproteins. V. A novel rapid procedure to screen apolipoprotein E polymorphism","volume":"29","author":"M. I. Kamboh","year":"1988","journal-title":"J Lipid Res"},{"key":"pone.0311878.ref028","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"M. M. Mielke","year":"2022","journal-title":"Nat Med"},{"key":"pone.0311878.ref029","doi-asserted-by":"crossref","first-page":"e0188802","DOI":"10.1371\/journal.pone.0188802","article-title":"Increased levels of plasma total tau in adult Down syndrome.","volume":"12","author":"T. Kasai","year":"2017","journal-title":"PLoS One"},{"key":"pone.0311878.ref030","doi-asserted-by":"crossref","first-page":"e0211575","DOI":"10.1371\/journal.pone.0211575","article-title":"Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients.","volume":"14","author":"M. Shinomoto","year":"2019","journal-title":"PLoS One"},{"key":"pone.0311878.ref031","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41398-021-01476-7","article-title":"Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer\u2019s disease.","volume":"11","author":"S. D. Chen","year":"2021","journal-title":"Transl Psychiatry"},{"key":"pone.0311878.ref032","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2021.1893","article-title":"Association of Apolipoprotein E \u025b4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome","volume":"78","author":"A. Bejanin","year":"2021","journal-title":"JAMA Neurol"},{"key":"pone.0311878.ref033","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"E. H. Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"pone.0311878.ref034","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.seizure.2010.04.008","article-title":"Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer\u2019s disease in Down syndrome","volume":"19","author":"R. De Simone","year":"2010","journal-title":"Seizure"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T18:31:06Z","timestamp":1733769066000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311878"}},"subtitle":[],"editor":[{"given":"Kensaku","family":"Kasuga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311878","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]}}}